Blog

First ‘off-the-shelf’ stem cell therapy gains central authorization in EU – The Pharma Letter


The Pharma Letter

First 'off-the-shelf' stem cell therapy gains central authorization in EU
The Pharma Letter
Japanese pharma company Takeda Pharmaceutical (TYO: 4502) and the Belgian biopharma that it is in the process of acquiring, TiGenix, achieved a notable milestone on Friday with the European Commission's approval of Alofisel (darvadstrocel). It has been
Stem cell therapy approved in Europe to treat fistulizing Crohn's diseaseHealio



all 3 news articles »

2018-03-23 NEWS
About Michael Zand

Leave a Reply

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.